The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
The Optimism Collective has unveiled OP Enterprise, a comprehensive blockchain infrastructure platform designed to give financial technology firms and institutions direct control over revenue and operations. The launch signals a pivotal shift towards institutional-grade Web3 solutions as regulatory clarity emerges.
Lean hog futures slipped lower on Friday, contrasting with a steady rise in the CME Lean Hog Index, as traders weighed softer cash prices against stronger wholesale pork values.
A dramatic reversal in precious metals markets saw silver crash 35% and gold fall 12% in a single session, testing a long-held crypto theory about capital rotation as Bitcoin demonstrates relative stability.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
For long-term investors, volatility presents both opportunity and peril. We examine one stock with explosive potential and two others where caution may be warranted amid shifting market dynamics.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
In a market fixated on tech giants, savvy investors are looking to regional financial institutions for sustainable growth. We analyze two banks with strong momentum and one where caution may be warranted, against a backdrop of shifting interest rates and economic uncertainty.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, they can also mask underlying vulnerabilities. We analyze three such stocks—Figs, Array Technologies, and Kforce—that currently present significant risks to investors, despite their seemingly accessible price tags.
As the tech world's giants build their AI ambitions, chip designer Arm Holdings stands at the center. With its Q3 earnings report on the horizon, investors are weighing whether its foundational role justifies a premium valuation.
With its stock near 52-week highs, Western Digital prepares to unveil its AI-driven storage roadmap at a pivotal New York event, seeking to transition its narrative from cyclical recovery to structural growth.
Peter McGuinness, the CEO who sought to reposition plant-based meat for mainstream consumers by moving beyond climate messaging, is departing Impossible Foods. His exit comes as the broader alternative protein sector faces significant sales declines and strategic recalibration.
DXC Technology met Q4 revenue targets with stable sales of $3.19B and an earnings surprise, but cautious guidance and stagnant organic growth highlight the challenges of its strategic transformation toward AI-native services.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
While Lindian Resources shares have retreated 13% recently, company insiders who bought stock over the past year are sitting on substantial paper profits, with one executive's purchase now valued at over seven times its cost.
Options strategist Rick Orford outlines a disciplined, top-down screening methodology to filter the market for optimal covered call candidates, emphasizing stock quality over mere premium yield.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Nasdaq Inc. reported stronger-than-expected fourth-quarter results, fueled by surging revenue from its technology solutions division and strategic AI initiatives, even as the company navigates a tighter margin environment.
